Text Size
S
M
L
Listen
Santen Global
menu
Patients
Healthcare Professionals
Careers
Investors
Listen
Tap on the left to use.
Who We Are
Message
Message from the CEO
Corporate Story
Corporate Story
CORE PRINCIPLE / Our Commitment
CORE PRINCIPLE / Our Commitment
Our Values
Our Values
History
History of Santen
Corporate Executives
Corporate Executives
Corporate Governance
Corporate Governance
Policies
Policies and Statements
Company Infomation
Overview / Map
Global Operation
What We Do
MTP & Santen 2030
Medium-term Management Plan
Santen 2030
Efforts to Enhance Patients' Satisfaction
Efforts to Enhance Product Safety
Efforts to Enhance Product Usability
Efforts to Address Untreated Patients
Research & Development
Research & Development
The Ophthalmic Product Process: R&D
Clinical Trial Information
Partnering
Santen's Partnership
Our Partners
Partnering Contact
Production
Production
Safety and Quality Assurance
The Ophthalmic Production Process: Production
Sales & Marketing
Sales & Marketing
Our Stories
Sustainability
Sustainability
Our Sustainability Commitment
Sustainability at Santen
Social
Access to Healthcare
Research & Development in Ophthalmology
Product Quality & Safety
Supply Chain
Human Rights
Talent
Digital Transformation (DX)
Governance
Corporate Governance
Compliance
Ethical Marketing
Risk Management
Information Security
Environment
Environmental initiatives
Measures against Climate Change
Environmental Load Reduction
Biodiversity
Disclosures Based on the TCFD Recommendations
Inclusion
Inclusive Society Santen Promotes
Inclusion Starting from Blind Football
Together with Society
With Employees
Related Information
Participating in the UN Global Compact
Social Contribution Activities
Stakeholder Engagement
Environment Data (up-to-date)
Social Data (up-to-date)
Governance Data (up-to-date)
GRI Standards Content Index
Sustainability Library
External Assessment
News
News
Show All
Press Release
IR News
Information
HOME
News
2024
2024 News
Press Release
IR News
Information
Press Release
11.07.2024
Santen and Arctic Vision execute a commercial collaboration agreement for ARVN001, a suprachoroidal space injection therapy for the treatment of uveitic macular edema
11.01.2024
Santen launches Rhopressa® ophthalmic solution 0.02% (netarsudil mesylate), in South Korea, for the treatment of patients with open-angle glaucoma or ocular hypertension
10.09.2024
Santen Announces Corporate Volunteer Partnership with Be My Eyes
09.26.2024
Santen applies for manufacturing and marketing approval in Japan for STN1012600 ophthalmic solution (sepetaprost ophthalmic solution), a treatment for glaucoma and ocular hypertension with a novel mechanism of action for lowering intraocular pressure
09.18.2024
Santen Publishes its Annual Integrated Report “Santen Report 2024”
Press Release
IR News
11.07.2024
Santen and Arctic Vision execute a commercial collaboration agreement for ARVN001, a suprachoroidal space injection therapy for the treatment of uveitic macular edema
11.07.2024
Santen Announces Share Buyback
11.07.2024
Santen Announces Cancellation of Treasury Shares
11.07.2024
Santen Announces Completion of Share Buyback
11.07.2024
Santen Reports the 2nd Quarter Fiscal 2024 Consolidated Performance
IR News
Information
10.01.2024
Santen Providing Disaster Relief to Communities Impacted by Heavy Rain in Noto Peninsula
08.05.2024
Cutting Back on Pouches and Medicine Bags Provided With Eye Drops -Santen’s Efforts to Reduce Single-Use Plastic to Decrease Our Environmental Footprint-
05.21.2024
Santen Recognized for Longstanding Commitment to Nippon Lighthouse Guide Dog Training Program
05.07.2024
17 Visually Impaired Children Participate in “17th Santen Brasaka Kids’ Camp in Kansai”
02.07.2024
Santen selected as "The Sustainability Yearbook Member" by S&P Global in the United States
Information
News Archive
